Sydney
Australia
The University of Sydney - Melanoma Institute Australia
melanoma, indoleamine 2,3-dioxygenase, epacadostat, pembrolizumab, immunotherapy
dedifferentiation, immunotherapy resistance, computational biology, MAPK inhibitor resistance
Dysfunctional CD8+ T cells, CD226 (DNAM-1), CD155 (PVR), Cancer immunotherapy, Melanoma, HNSCC, adoptive cell transfer therapy